Intended for healthcare professionals

Letters “Liquid biopsy” for cancer screening

Grail’s reply to editorial on “liquid biopsy” for cancer screening

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n596 (Published 03 March 2021) Cite this as: BMJ 2021;372:n596
  1. Harpal Kumar, president
  1. Grail Europe, New Penderel House, London WC1V 7HP, UK
  1. hkumar{at}grailbio.com

I write in response to some of the key points raised in Barclay and Bradley’s editorial regarding the partnership between Grail and NHS England.1

Grail’s multi-cancer early detection (MCED) test represents one of the first examples of an innovation developed by a private company but intended for public health uptake. Adding MCED to ongoing single cancer screening could dramatically improve …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription